Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Curbing Unnecessary Vitamin D Testing.

NEJM catalyst innovations in care delivery·2026
Same author

Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.

Nature cancer·2026
Same author

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Cancer research communications·2026
Same author

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Blood advances·2026
Same author

Clinical and molecular features of primary gliosarcoma with digital spatial whole-transcriptome analysis of glial and mesenchymal components.

Brain pathology (Zurich, Switzerland)·2026
Same author

Amelioration of manganese-induced oxidative stress and pathological damage in the intestine of Micropterus salmoides by fermented Chinese herbal.

Fish physiology and biochemistry·2026

Related Experiment Video

Updated: May 21, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.

Jennifer Dunlap1, Carol Beadling, Andrea Warrick

  • 1Department of Pathology, Oregon Health & Science University, Portland, OR 97239, USA.

Human Pathology
|June 5, 2012
PubMed
Summary

A new high-throughput mass spectrometry method efficiently identifies multiple gene mutations in acute myeloid leukemia (AML). This genetic profiling aids in classifying AML subtypes and selecting targeted therapies.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

Related Experiment Videos

Last Updated: May 21, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Acute myeloid leukemia (AML) classification increasingly relies on genetic analysis.
  • The number of identified AML mutations is rapidly expanding, necessitating advanced diagnostic tools.

Purpose of the Study:

  • To evaluate a high-throughput, multiplex mass spectrometry-based approach for comprehensive mutation analysis in AML.
  • To assess the feasibility and utility of this method in a clinical setting for leukemia genotyping.

Main Methods:

  • Screened 107 AML cases using a multiplex panel for 344 point mutations across 31 leukemia-associated genes.
  • Employed multiplex polymerase chain reaction (PCR) and primer extension, followed by analysis on a Sequenom MassARRAY system.
  • Compared results with cytogenetics and standard PCR screening for key mutations (NPM1, CEBPA, FLT3-ITD, KIT).

Main Results:

  • The multiplex panel detected mutations in 58% of AML cases with normal cytogenetics and 21% with abnormal cytogenetics.
  • Combined with standard PCR, mutation detection reached 78% in normal cytogenetic cases, with 42% harboring multiple mutations.
  • Cases with abnormal cytogenetics rarely showed multiple mutations (1.5%), indicating distinct biological pathways.

Conclusions:

  • Broad-based mutation profiling using multiplex mass spectrometry is feasible and valuable in clinical AML diagnosis.
  • This approach can refine prognostic subgrouping and guide patient selection for targeted therapy trials.
  • The findings suggest different genetic underpinnings for AML based on cytogenetic status.